“A new paradigm for treating metabolic diseases.”
ABOUT US
Eternygen is a Berlin based start up founded in June 2012 focusing on research and development of innovative drugs using a network of renowned scientists and contract research organizations. The main focus of Eternygen’s development and core competences of its founders are research and development of new drugs for aging and dietary-related metabolic diseases with dramatically increasing prevalences in the last decades. Eternygen’s research addresses the sodium coupled citrate transporter NaCT which is a key regulator of citrate metabolism involved in the pathogenesis of chronic kidney diseases, fatty liver, diabetes and obesity.
The company’s emphasis is the development of a safe and effective drug for treatment of these widespread diseases via targeted adjustment of underlying metabolic failure.
RESEARCH & DEVELOPMENT
LITERATURE & PAPER
Zahn et al. 2023 – Metabolites
Targeting Longevity Gene SLC13A5: A Novel Approach to Prevent Age-Related Bone Fragility and Osteoporosis
Sandforth et al. 2023 – The Lancet Diabetes & Endocrinology
Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS)
Gill et al. 2023 – BMC medicine
The citrate transporter SLC13A5 as a therapeutic target for kidney disease: evidence from Mendelian randomization to inform drug development
Stefan et al. 2023 – Cell Metabolism
The role of hepatokines in NAFLD
OUR TEAM
Partners & Collaborators
